This recent study compared orthostatic hypotension outcomes among 2 patient populations, both with chronic kidney disease (CKD), who were or were not living with diabetic nephropathy (DNP).
Researchers from Bezmialem Vakif University in Turkey found the occurrence of orthostatic hypotension (OH) to be similar among patients with chronic kidney disease (CKD) who do or do not have comorbid diabetic nephropathy (DNP). Their study, published recently in Kidney and Blood Pressure Research, investigated the subtype of low blood pressure that occurs upon standing up after an individual has been sitting or lying on their back.
According to the authors, “Diabetic nephropathy is one of the microvascular complications of diabetes. It is also the most common cause of chronic kidney disease.” For their study, they used the American Academy of Nephrology’s definition of OH, which is a 20 mm Hg or 10 mm Hg decrease in systolic or diastolic blood pressure, respectively, in the 3 minutes after rising from either sitting or lying down.
“Studies show that OH is an important parameter affecting quality of life,” the authors wrote, but no studies have investigated a possible link between OH and DNP. “The aim of this study was to investigate and compare the presence and affecting factors of OH among patients with and without diabetic nephropathy.”
They did see a slight difference between the DNP and non-DNP groups regarding the presence of OH, but this difference was deemed not significant, at 70.5% and 61.7% (P = .181), respectively. Neither was the result of change in systolic blood pressure, at 24.00 (range, 10.00-32.00) mm Hg for the DNP cohort and 24.00 (range, 13.75-30.25) mm Hg for the non-DNP cohort.
Significant differences were seen, however, regarding change in diastolic blood pressure and occurrence of OH when CKD medication class was considered:
In addition, OH occurred much more often among the male patients than the female patients, at 74.7% vs 60.0% (P = .026); the mean (SD) uric acid level was determined to be significantly higher in the DNP vs non-DNP group for those with OH, at 7.18 (1.55) vs 6.36 (1.65) mg/dL (P = .017); and mean serum albumin levels were significantly higher among all patients with OH compared with those without OH, at 42.10 (3.13) vs 39.60 (3.72) g/L (P <. 001).
All patients included in this analysis were outpatients who visited the Nephrology Outpatient Clinic at Bezmialem Vakif University Hospital between February and August 2019. The 2 study groups (112 with DNP; 94 without) were matched for age, gender, and estimated glomerular filtration rate (eGFR) distributions. Overall, both groups were predominantly male (54%, DNP; 57%, without) and of equal mean (SD) age (62.56 [9.35] and 62.23 [10.08] years, respectively; P = .809). Except for insulin use in the DNP group, the top 3 most common medications used by both patient groups were diuretics (34.0% in the non-DNP group; 62.5% in the DNP group; P < .001), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (41.5% and 52.7%, respectively; P = .109), and CCBs (48.9% and 60.7%; P = .090)
“In this study, it was shown for the first time that whether the etiology of CKD is DNP or not does not influence the OH prevalence in these patients,” the authors wrote.
However, they do cite several limitations to their findings, including their small sample size, lack of data on diabetes duration among their study subjects, and that blood pressure measurements were only taken once.
They recommend that patients with comorbid CKD and diabetes be evaluated for OH at every visit, along with potential causes, “because necessary precautions should be taken to prevent future OH-related complications.”
Reference
Gamze A, Kazancıoğlub R, Elçioğlub OC, et al. Comparative evaluation of orthostatic hypotension in patients with diabetic nephropathy. Kidney Blood Press Res. 2021;1-7. doi:10.1159/000517316
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
Dr Madeleine McDowell Discusses How CKD Disparities, Social Challenges Impact Health Care Access
October 4th 2023Madeleine McDowell, MD, hopes these data insights will help change providers' behavior in terms of adopting earlier and more regular screening for chronic kidney disease (CKD).
Read More
Advocating for All Patients With Chronic Kidney Disease
April 26th 2022Chronic kidney disease is the fastest-growing noncontagious disease in the United States. On this episode of Managed Care Cast, we speak with Mike Spigler, vice president of patient support and education for the American Kidney Fund, who is spearheading the Unknown Causes of Kidney Disease Project, which aims to help underserved patients get to the root cause of their kidney disease, while also helping to solve this mystery for a broader patient population.
Listen